EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Dieter Weinand

Keynote

Bayer AG

Bill Sibold

Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech

Sanofi Genzyme

07:45 18:30 (645 mins)

Main agenda

Registration and Exhibition open

07:45 10:30 (165 mins)

Main agenda

Continental Breakfast

09:00 10:30 (90 mins)

Main agenda

Routes of commercialization

This panel will discuss the market access strategies, transitions to and from the clinic, supply change development, and partnering approaches that allow a company to juggle the dynamic, changing requirements of the commercialization process.  The panelists will address issues from early stage to launch, and will use real world examples to illustrate how constant forward planning, early regulatory engagement and a flexible partnering strategy is essential to commercial success.

  • Moderator Anna Casse - Managing Partner, Alacrita
  • Panelist Johannes Clemens - Key Account Manager, Business Development, Vetter Pharma International
  • Panelist Laurent Foetisch - Managing Director, Supply Chain Operations SA
  • Panelist Anant Murthy - VP, Market Access & Policy, Europe & Canada, Alnylam Pharmaceuticals
  • Panelist Matthew Zustiak - Head of Upstream Process Development, Patheon, part of Thermo Fisher Scientific

09:00 10:30 (90 mins)

Main agenda

The evolving role of Real World Evidence in regulatory approval and reimbursement decisions

Panelists discuss how real world data is impacting clinical development today.  This session will identify the groups in the development process that demand real world evidence, what they are looking for and the considerations that companies need to plan for in order to ensure effective implementation of data.

  • Moderator Leora Schiff - Principal, Altius Strategy Consulting
  • Panelist Athula Herath - Global Head, Real World Evidence Disease Epidemiology, Novartis

09:00 10:30 (90 mins)

Main agenda

Successful corporate communications in a changing media and investment world

Biotech companies increasingly have difficulties getting their story across to media and the investment community. For one, more and more media cannot afford trained science journalists any more. Their successors usually don’t have a background in science, are not familiar with the industry and lack a carefully built network of science and industry specialists adamant for the gathering and evaluation of news.

On the other hand, many biotech professionals still underestimate the role of having a clear story and vision they can pitch to investors to convince them of a solid business case. This has become increasingly important as many biotech companies have started to look for investors outside the traditional biotech investment community.

Therefore, biotech companies need to communicate their progress to a larger audience. This is not only important for public companies. Private companies, too, must develop broad communication skills in order to succeed. In this panel, we will discuss the needs of both healthcare-savvy media / investors and generalists and how companies can address these needs.

  • Moderator Ludger Weß - Managing Partner, akampion
  • Panelist Sascha Karberg - Science Writer, transkript/Tagesspiegel
  • Panelist Cormac Sheridan - Science Journalist, BioWorld/Nature
  • Panelist Mike Ward - Global Director of Content, Informa Pharma Insights

10:00 18:30 (510 mins)

Main agenda

One-to-one Meetings

10:45 11:15 (30 mins)

Main agenda

Welcome and Opening Remarks

  • Speaker Anna Chrisman - Group Managing Director, EBD Group
  • Speaker Ramona Pop - Senator, Economics, Energy and Public Enterprises
  • Speaker David Thomas - Senior Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)

11:15 11:30 (15 mins)

Main agenda

Keynote

  • Speaker Dieter Weinand - Member of the Board of Management and President Pharmaceuticals, Bayer AG

11:30 12:30 (60 mins)

Main agenda

Opening Plenary - Breaking down walls: Keeping collaboration at the center of biotech

Biotech has thrived because of the collaborative nature of its business model. The plenary session will address the new walls being erected within the industry, in policy, business, and science, which will require the same cooperation to break down.

  • Panelist Bill Sibold - Executive VP and Head, Sanofi Genzyme
  • Moderator Kate Bingham - Managing Partner, SV Life Sciences Advisers
  • Panelist Zaki Hosny - Senior Advisor, Albright Stonebridge Group
  • Panelist Claudia Karnbach - Head, Business Development and Licensing, Specialty Medicine, Pharmaceuticals Division, Bayer
  • Panelist Richard Mason - Head of London Innovation Centre, Johnson & Johnson Innovation, EMEA

12:00 14:00 (120 mins)

Main agenda

Luncheon

13:30 14:30 (60 mins)

Main agenda

New models for growth financing

This panel will discuss the latest innovative trends in funding company growth and drug pipelines, including royalty monetization, strategic drug development funding and new investment models stemming from Emerging Markets.

  • Moderator Ruediger Hermann - Partner, Corporate Life Sciences, Dechert LLP

13:30 14:30 (60 mins)

Main agenda

Developing solutions for pediatric diseases

  • Moderator Hubert Birner - Managing Partner, TVM Life Science Management and TVM Capital
  • Panelist Elizabeth Aylward - Director, Office of Science-Industry Partnerships, Seattle Children’s Research Institute
  • Panelist Arndt Rolfs - CEO, Centogene
  • Panelist Chris Schelling - CEO, Acer Therapeutics
  • Panelist Kim Stratton - Head, International Commercial, Shire

14:45 15:45 (60 mins)

Main agenda

Targeting the microbiome: From scientific evidence to regulatory approval

In recent years, scientific evidence has turned the spotlight on the microbiome as a separate organ that plays a vital role in many human diseases. As a result, funding for microbiome companies continues to grow rapidly, setting the stage for more companies to explore the therapeutic value of harnessing the microbiome to develop novel treatments. As the microbiome field shifts from scientific proof-of-concept stage towards product development, new challenges are raised in respect to choosing effective development pathways to reach the appropriate market segments. There is a variety of strategies to choose from in the microbiome field, whether companies are focused on developing new medicines and medical nutrition, products for health maintenance, which can be sold as OTC products, nutritional supplements or functional foods; or, occasionally, microbiome-derived products approved as medical devices. Innovative companies in the field need to select the best clinical and regulatory pathway for their product plan based on their scientific knowledge and their projected strategy. This involves early choices such as: which customers to target, which modality to base the product on (live organism(s), biologics, small molecules), which regulatory regimen to choose (prescription drug, food, device—and the many subdivisions of each of those categories), and what are the operational and financial consequences of these choices on the company’s business plan. Join us as we discuss examples of different pathways to pursue, steps where the collaboration with regulatory agencies is required, and how to mix the different ingredients for a successful business strategy.

  • Moderator Douglas MacDougall - President, MacDougall Biomedical Communications
  • Panelist Patrice Cani - Université Catholique de Louvain, FNRS-WELBIO, Brussels, Belgium
  • Panelist David Donabedian - Co-Founder and CEO, Axial Biotherapeutics
  • Panelist Eric de la Fortelle - Venture Partner, Seventure

16:00 17:00 (60 mins)

Main agenda

Next wave immunotherapy: The future including and beyond checkpoints

With immune checkpoint inhibitors such as Yervoy, Opdivo, and Keytruda having demonstrated an ability to extend survival across heavily pretreated tumor types, all eyes are now looking ahead to how the effect of size and addressable patient populations can be expanded upon. Indeed, a range of modalities have emerged as potential candidates for checkpoint combination regimens, each poised to address “cold” or otherwise IO-resistant patients. Many questions still exist, including which mechanisms will be best suited to unleash the full power of the anticancer immune response, in what patients, and over what time horizons will various developments continue to play out. Join our distinguished panel as we discuss and debate some of the finer points surrounding clinical and commercial issues in oncology and look to achieve a deeper understanding about who and how to achieve relevance in the emerging IO landscape.

  • Moderator Joel Sandler - Associate Principal, Defined Health
  • Panelist Kaan Certel - Head of External Innovation Oncology, Business Development and Licensing, Sanofi
  • Panelist Nouhad Husseini - VP, Head of Business Development, Regeneron
  • Panelist Bernd Mühlenweg - Chief Business Officer, Nanobiotix
  • Panelist Matt Roden - VP, Global Business Development Assessment and Strategic Corporate Development, Bristol-Myers Squibb

17:15 18:15 (60 mins)

Main agenda

Cell and Gene Therapies

  • Moderator John Carroll - Co-Founder and Editor, Endpoints

13:30 14:30 (60 mins)

Main agenda

Funding Discovery

This panel will discuss the latest innovative trends in funding company growth and drug pipelines, including royalty monetization, strategic drug development funding and new investment models stemming from Emerging Markets.

  • Panelist Philipp Bürling - CFO and Co-Founder, NUMAFERM GmbH
  • Panelist Andrew Hopkins - CEO, Exscientia
  • Panelist Raphael Wisniewski - Partner, Edmond de Rothschild Investment Partners

14:45 15:45 (60 mins)

Main agenda

What the deals of 2017 mean for 2018

This panel will examine the deal trends of 2017. What are the drivers? Who are the players? What are the structures? Can we expect to see these trends continue into 2018? Join us for a deep dive into the deals of 2017.

  • Moderator David McClain - Principal, ClearView Healthcare Partners
  • Panelist Ron Newbold - VP, Global Scouting, External R&D Innovation, Pfizer
  • Panelist Ben Thorner - Senior VP, Business Development and Licensing, MSD

16:00 17:00 (60 mins)

Main agenda

Building the future of the European public market

The European biotech market has much going for it: strong M&A, strong investment, exciting young companies with the potential for lucrative exits. This session will discuss how the strengths of the industry can be consolidated through the further development of a European public market.

  • Moderator Olivier Litzka - Partner, Edmond de Rothschild Investment Partners
  • Panelist Oscar Izeboud - Managing Director, NIBC Bank
  • Panelist Frederic Martineau - Business Development and Client Coverage Manager, Ile de France and East Regions, Euronext
  • Panelist Simon Moroney - CEO, MorphoSys

17:15 18:15 (60 mins)

Main agenda

Answering the million dollar question: Partner or go it alone?

Dealmaking in life sciences has been robust in 2017 and remains a seller’s market as buyers narrow their therapeutic areas of focus and fiercely compete for entry and leadership in hot therapeutic areas. At the same time, true innovators can expect to benefit from the emergence of new buyers and more financing options from the capital markets as well as unique partnering and outsourcing scenarios, permitting them to hold on to assets through to commercialization in some disease areas. This panel will discuss the many opportunities available to sellers and considerations for making the decision between partnering and going it alone.

  • Moderator Neel Patel - Managing Director, INC Research/inVentiv Health Consulting
  • Panelist Jennifer Laird - Senior Director, Neuroscience, Eli Lilly
  • Panelist Philippe Lopes-Fernandes - Senior VP, Head of Global Licensing and Business Development, Merck KGaA
  • Panelist Nerida Scott - VP, New Ventures and Transactions, Johnson & Johnson Innovation

16:05 16:25 (20 mins)

Main agenda

Break and Breathe

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. 

Open to all. No prerequisites required. Standing and seated positions only.


17:05 17:25 (20 mins)

Main agenda

Break and Breathe

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. Open to all. No prerequisites required. Standing and seated positions only.

18:00 18:45 (45 mins)

Main agenda

Champagne reception at EBD Group booth

19:00 22:30 (210 mins)

Main agenda

Evening Networking Reception with Buffet-style Dinner

Venue: 

Palais am Funkturm | Hammarskjöldplatz | 14055 Berlin

The Palais am Funkturm is Berlin’s largest ballroom—a venue for balls, banquets and receptions, with the unique charm of the 50s. With its elegantly curved patterns and original interior it is a highly popular party location. Experience the exclusive atmosphere under a ceiling decorated with gold leaf as well as the impressive sandstone entrance hall. Located at the other end of Messe Berlin, the Palais am Funkturm is only at a short distance from the CityCube.